American Society of Hematology Annual Meeting and Exposition

Canada Approves High-Concentration Humira Biosimilar

January 3rd 2023

Article

Health Canada has approved the high-concentration version of Samsung Bioepis and Organon’s Hadlima, a citrate-free adalimumab biosimilar referencing Humira.

SB12 Eculizumab Biosimilar Candidate Demonstrates PK, PD Equivalence in Phase 1 Trial

December 18th 2021

Article

In a pharmacokinetic (PK) and pharmacodynamic (PD) trial in healthy participants, Samsung Bioepis' SB12 eculizumab biosimilar candidate demonstrated equivalence to Soliris, the reference product.

Romiplostim Biosimilar Study Demonstrates Safety, Efficacy in Real-World India Population

December 8th 2020

Article

A high overall response rate of 93% was observed for patients with immune thrombocytopenic purpura who received romiplostim biosimilar.

Celltrion's Rituximab Biosimilar Demonstrates Equivalence in Follicular Lymphoma

December 7th 2020

Article

A long-term, comparative, phase 3 trial of CT-P10 vs the rituximab originator product has provided evidence of biosimilar value in this blood disorder.

Investigators: Biosimilar Pegfilgrastim Has Advantages Over Wearable Injector

December 1st 2020

Article

The wearable injector has a failure rate that adds hospitalization costs; therefore, biosimilar pegfilgrastim may hold cost advantages, investigators conclude.

FN Prophylaxis With Biosimilar Filgrastim Generates Substantial Savings Versus Pegfilgrastim On-Body Injector

December 5th 2018

Article

There are several options for the prophylaxis of febrile neutropenia (FN), including pegfilgrastim delivered in an on-body injector (OBI), a single injection of pegfilgrastim, and daily injections with reference filgrastim or Sandoz’ biosimilar filgrastim.

Biosimilar Beats Subcutaneous Rituximab on Cost Savings in NHL

December 5th 2018

Article

The launch of biosimilar rituximab is an eagerly awaited event among US healthcare stakeholders who are cognizant of the high cost of intravenously (IV) administered rituximab in treating non-Hodgkin lymphoma (NHL). At the same time, another innovation in rituximab delivery—a subcutaneously administered rituximab formulation—has the potential to save both cost and time.

CT-P10 Is Similar to Reference Rituximab in Previously Untreated Advanced Follicular Lymphoma

December 4th 2018

Article

The study’s authors concluded that, at the median follow-up of 23 months, the data demonstrated comparable progression-free survival, sustained response, and overall survival between both the biosimilar and the reference product.

Tbo-Filgrastim Delivers VHA Cost Savings, but Could a Change of Strategy Do More?

December 4th 2018

Article

For health systems like the Veterans Health Administration (VHA), where controlling costs while providing high-quality care is of heightened concern, achieving the best value for money in the prophylaxis of neutropenia can help to control the cost of cancer care.

More Data Underscore the Safety and Efficacy of CT-P10 in Hematological Conditions

December 4th 2018

Article

Celltrion’s CT-P10, a biosimilar rituximab that was FDA approved under the brand name Truxima in November 2018, is already in wide use for a host of indications in many regulatory territories. During this week’s 60th Annual Meeting and Exposition of the American Society of Hematology in San Diego, California, multiple research teams are reporting data that underscore the safety and efficacy of CT-P10 in hematological conditions.